Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2012 1
2013 2
2015 3
2016 4
2017 1
2019 1
2020 2
2021 6
2022 3
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. Among authors: repantis d. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E. Goodwin GM, et al. Among authors: repantis d. J Affect Disord. 2023 Apr 14;327:120-127. doi: 10.1016/j.jad.2023.01.108. Epub 2023 Feb 4. J Affect Disord. 2023. PMID: 36740140 Free article. Clinical Trial.
Non-pharmacological cognitive enhancement.
Dresler M, Sandberg A, Ohla K, Bublitz C, Trenado C, Mroczko-Wąsowicz A, Kühn S, Repantis D. Dresler M, et al. Among authors: repantis d. Neuropharmacology. 2013 Jan;64:529-43. doi: 10.1016/j.neuropharm.2012.07.002. Epub 2012 Jul 22. Neuropharmacology. 2013. PMID: 22828638 Review.
Hacking the Brain: Dimensions of Cognitive Enhancement.
Dresler M, Sandberg A, Bublitz C, Ohla K, Trenado C, Mroczko-Wąsowicz A, Kühn S, Repantis D. Dresler M, et al. Among authors: repantis d. ACS Chem Neurosci. 2019 Mar 20;10(3):1137-1148. doi: 10.1021/acschemneuro.8b00571. Epub 2019 Jan 2. ACS Chem Neurosci. 2019. PMID: 30550256 Free PMC article. Review.
Memory, Authenticity, and Optogenethics.
Bublitz JC, Repantis D. Bublitz JC, et al. Among authors: repantis d. AJOB Neurosci. 2021 Jan;12(1):30-32. doi: 10.1080/21507740.2020.1866102. AJOB Neurosci. 2021. PMID: 33528333 No abstract available.
Control side effects of the psychedelic renaissance.
Bublitz C, Langlitz N, Repantis D. Bublitz C, et al. Among authors: repantis d. Nature. 2023 Aug;620(7973):277. doi: 10.1038/d41586-023-02495-8. Nature. 2023. PMID: 37553462 No abstract available.
23 results